Optimizing decision-making for DCIS: Facts over fear
Menée à partir de données portant sur 1 362 patientes atteintes d'un carcinome canalaire in situ et ayant reçu un traitement conservateur (durée médiane de suivi : 16 ans ; âge au diagnostic : inférieur ou égal à 75 ans), cette étude évalue l'association entre les résultats d'un test basé sur l'expression de 21 gènes et la mortalité spécifique
Over the past fewdecades there have been attempts to fine-tune the treatment of breast cancer,andtailor therapy to the characteristics of the disease and preferences of the patient, and in particular, avoid overtreatment for lower risk disease. In the case of non-invasive breast cancerincluding ductal carcinoma in situ(DCIS), the need has been particularly critical given the robust available body of evidencesuggests only minimal impact of treatment modalities on survival. Therefore,we read with interest the manuscript by Dr. Rakovitch and colleagues, “21-Gene Assay Predicts Breast Cancer Mortality in Ductal Carcinoma in Situ” in this week’s issue of the JNCI:Journal of the National Cancer Institute.1In this article, the authors performed a population-based analysis of DCIS patients treated with breast-conserving surgery (BCS).
Journal of the National Cancer Institute , éditorial en libre accès, 2019